Cite
HARVARD Citation
Kurino, T. et al. (2020). Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models. Journal for immunotherapy of cancer. 8 (1), p. . [Online].